Profile data is unavailable for this security.
About the company
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
- Revenue in USD (TTM)0.00
- Net income in USD-464.20m
- Incorporated2018
- Employees362.00
- LocationImmunovant Inc320 West 37Th StreetNEW YORK 10018United StatesUSA
- Phone+1 (917) 580-3099
- Fax+1 (302) 636-5454
- Websitehttps://immunovant.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.01bn | 59.00 | -- | 11.64 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Crinetics Pharmaceuticals Inc | 1.54m | -423.10m | 4.05bn | 437.00 | -- | 3.77 | -- | 2,639.66 | -4.53 | -4.53 | 0.0165 | 11.34 | 0.0014 | -- | 0.2622 | 3,512.59 | -39.66 | -36.96 | -42.19 | -39.20 | -- | -- | -27,563.32 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 4.06bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.15bn | 113.00 | -- | 5.86 | -- | 1,910.91 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 4.25bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 598.70m | -14.06m | 4.49bn | 499.00 | -- | 19.16 | -- | 7.50 | -0.0458 | -0.0458 | 1.94 | 0.7469 | 0.7234 | 0.4175 | 5.65 | 1,199,808.00 | -1.70 | -23.63 | -2.17 | -28.66 | 89.77 | 89.34 | -2.35 | -53.29 | 2.09 | 0.8067 | 0.6298 | -- | 32.29 | 23.72 | 62.99 | -- | -29.23 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.63bn | 196.00 | -- | 6.86 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.69bn | 196.00 | -- | 18.61 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Celcuity Inc | 0.00 | -162.72m | 4.84bn | 87.00 | -- | 38.67 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -210.69m | 4.84bn | 218.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -23.87 | -- | -25.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -36.72 | -- | -- | -- |
| Protagonist Therapeutics Inc | 209.22m | 45.91m | 5.09bn | 128.00 | 129.07 | 7.88 | 107.59 | 24.35 | 0.6313 | 0.6313 | 3.26 | 10.34 | 0.3205 | -- | 52.34 | 1,660,452.00 | 7.03 | -7.11 | 7.55 | -7.93 | -- | -- | 21.94 | -21.29 | -- | -- | 0.00 | -- | 624.06 | 351.71 | 448.54 | -- | 6.98 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.24bn | 362.00 | -- | 5.31 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Alkermes Plc | 1.52bn | 338.06m | 5.48bn | 1.80k | 16.43 | 3.16 | 14.87 | 3.60 | 2.02 | 2.02 | 9.06 | 10.50 | 0.6784 | 1.11 | 4.20 | 845,187.80 | 15.08 | 6.99 | 19.01 | 9.14 | 86.04 | 83.31 | 22.22 | 10.68 | 3.27 | -- | 0.00 | 0.00 | -6.36 | 5.87 | -28.32 | -- | -18.11 | -- |
| Immunitybio Inc | 82.56m | -348.62m | 5.86bn | 673.00 | -- | -- | -- | 70.93 | -0.4079 | -0.4079 | 0.0965 | -0.5323 | 0.1869 | 0.0857 | 4.56 | 121,404.40 | -78.93 | -109.27 | -91.33 | -251.12 | 90.40 | -- | -422.38 | -11,599.51 | 5.65 | -2.20 | 2.77 | -- | 2,270.58 | 46.27 | 29.09 | -- | 9.95 | -- |
| Cogent Biosciences Inc | 0.00 | -214.77m | 6.40bn | 205.00 | -- | 26.26 | -- | -- | -1.77 | -1.77 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -72.69 | -57.20 | -84.75 | -63.62 | -- | -- | -- | -9,345.59 | -- | -- | 0.1276 | -- | -- | -- | -30.01 | -- | 76.98 | -- |
Data as of Feb 13 2026. Currency figures normalised to Immunovant Inc's reporting currency: US Dollar USD
37.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 14.72m | 8.40% |
| Deep Track Capital LPas of 31 Dec 2025 | 11.53m | 6.58% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.14m | 4.08% |
| Armistice Capital LLCas of 30 Sep 2025 | 5.84m | 3.33% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 5.46m | 3.11% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.29m | 3.02% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 5.16m | 2.95% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.79m | 2.16% |
| Point72 Asset Management LPas of 30 Sep 2025 | 3.48m | 1.99% |
| Morgan Stanley Investment Management, Inc.as of 31 Dec 2025 | 3.20m | 1.83% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
